The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks
to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in
improvement in their liver disease as measured by changes in the nonalcoholic fatty liver
disease (NAFLD) activity score (NAS).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)